220 - Pioneering Drug Development for Hearing Loss with Dr. Jonathan Kil

220 - Pioneering Drug Development for Hearing Loss with Dr. Jonathan Kil

In this episode, we welcome Dr. Jonathan Kil, the CEO and CMO of Sound Pharmaceuticals to discuss the latest developments in hearing loss treatment. With a distinguished background in auditory neuroscience and otolaryngology, Dr. Kil co-founded Sound Pharmaceuticals over 22 years ago with a mission to develop drug-based therapies for sensorineural hearing loss and tinnitus. He has led the company’s research and development strategy, securing numerous NIH and Department of Defense awards, and spearheading numerous clinical studies. Dr. Kil recounts the journey of Sound Pharmaceuticals over the past two decades, highlighting the challenges faced and milestones achieved. He focuses on the development of SPI-1005. SPI-1005 is an investigational drug that contains ebselen, a small molecule that is a new chemical entity, under FDA classification, an innovative drug currently in clinical trials for Meniere's disease, noise-induced hearing loss, and aminoglycoside ototoxicity. Dr. Kil emphasizes the importance of their work, explaining how these treatments aim to provide better solutions for patients and improve their quality of life. Dr. Kil recounts the journey of Sound Pharmaceuticals over the past two decades, highlighting the challenges faced and milestones achieved. He focuses on the development of SPI-1005, an investigational drug containing ebselen, a novel anti-inflammatory compound that mimics and induces the activity of Glutathione Peroxidase, an enzyme critical to hearing and balance. Currently in clinical trials, SPI-1005 has shown safety and efficacy in treating three different forms of acquired sensorineural hearing loss in adults: loud sound exposure or acute noise-induced hearing loss, Meniere's disease, and antibiotic-induced ototoxicity. Dr. Kil explains the science behind these innovative therapies, the potential impact they may have, and the rigorous steps being taken to bring them to market. The conversation provides a unique perspective on the current state and future of pharmaceutical treatments for hearing loss and other inner ear conditions.


Learn more about Sound Pharmaceuticals here: https://soundpharma.com Be sure to subscribe to our YouTube channel for the latest episodes each week, and follow This Week in Hearing on LinkedIn and X (formerly Twitter):

  • https://www.linkedin.com/company/this-week-in-hearing/
  • https://twitter.com/WeekinHearing

Tämä jakso on lisätty Podme-palveluun avoimen RSS-syötteen kautta eikä se ole Podmen omaa tuotantoa. Siksi jakso saattaa sisältää mainontaa.

Jaksot(376)

368 - Listen Up: A New Push to Make Hearing Screening Routine at 50

368 - Listen Up: A New Push to Make Hearing Screening Routine at 50

Hearing loss often develops gradually, which means many people may not recognize changes until they begin interfering with everyday communication. A new national initiative is looking to change that b...

29 Syys 16min

367 - Oticon Reveal Hearing Aids: Inside the New Dual AI Technology

367 - Oticon Reveal Hearing Aids: Inside the New Dual AI Technology

Oticon’s new Reveal hearing aid platform introduces a Dual AI approach designed to manage speech and contextual sounds while preserving the broader sound environment around the listener. Andrew Bellav...

16 Syys 35min

366 - FDA Expands Pediatric Cochlear Implant Candidacy: What’s Changed?

366 - FDA Expands Pediatric Cochlear Implant Candidacy: What’s Changed?

Pediatric cochlear implant candidacy has expanded significantly in recent years, creating opportunities for earlier intervention and opening the door to implantation for children who may not have been...

10 Syys 24min

365 - Beyond the Audiology Appointment: How HLAA Supports People with Hearing Loss

365 - Beyond the Audiology Appointment: How HLAA Supports People with Hearing Loss

For people with hearing loss, many of the biggest challenges happen outside the clinic—from navigating difficult listening situations to managing the emotional and social impact of hearing loss.Shari ...

8 Syys 24min

364 - Inside Fortell’s Push Into the Prescription Hearing Aid Market

364 - Inside Fortell’s Push Into the Prescription Hearing Aid Market

Fortell is taking an unusual path for a hearing aid startup: entering the prescription hearing aid market with proprietary AI technology, its own clinics, and a care model built around audiologists.Sh...

2 Syys 38min

363 - Phonak EON Hearing Aids Deep Dive: Smaller Sphere, Smarter AI and Auracast

363 - Phonak EON Hearing Aids Deep Dive: Smaller Sphere, Smarter AI and Auracast

Phonak’s new EON hearing aid platform brings a smaller Sphere design, a new HYPERSONIC AI chip, expanded Spheric Speech Clarity, improved wind noise management, and Auracast connectivity.Andrew Bellav...

31 Elo 48min

362 - From Captions to Context: Rylo’s Vision for AI-Powered Communication

362 - From Captions to Context: Rylo’s Vision for AI-Powered Communication

AI-powered captions are becoming increasingly common, but Rylo CEO and co-founder Tomer Aharoni believes accessible communication needs to go much further than simply converting speech into text.Shari...

27 Elo 19min

361 - Inside Signia MaX Hearing Aids: Four DNNs and a New Approach to Sound Processing

361 - Inside Signia MaX Hearing Aids: Four DNNs and a New Approach to Sound Processing

What changes when a hearing aid uses four specialized deep neural networks at the same time? Andrew Bellavia travels to Munich for an early look at Signia MaX, the company’s new hearing aid platform b...

24 Elo 33min

Suosittua kategoriassa Terveys ja hyvinvointi

unicast
vakeva-elama-viisaampi-mieli-vahvempi-keho
aamukahvilla
rss-pitaisko-erota
psykopodiaa-podcast
tiedenaiset-podcast
meditaatiot-suomeksi
rss-pt-paahtio
katilon-kahvitunti
rss-kuumilla-aalloilla
voi-hyvin-meditaatiot-2
selviytyjat-tarinoita-elamasta
rss-uplevel-by-sonja-hannus
paritellen
terapiassa
rss-ehjaksi
rss-voimatarinat-aanessa-vahvat-naiset
rss-terapiaklubi
rss-hereilla
rss-duodecim-lehti